Hexagon Capital Partners’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-13
Closed -$2.16K 1479
2022
Q4
$2.16K Buy
+13
New +$2.66K ﹤0.01% 1072

Other funds holding LABD

Hexagon Capital Partners's LABD Position: Q1 2023 in Review

Hexagon Capital Partners sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2023, closing a stake of 13 shares — an estimated $2.16K sold.

Hexagon Capital Partners first reported a position in LABD in Q4 2022 and held it in 1 quarter. The position peaked at $2.16K in Q4 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2023.

  • Hexagon Capital Partners reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 13 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2023, an estimated $2.16K.
  • Hexagon Capital Partners first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2022 and held it in 1 quarter.
  • Hexagon Capital Partners's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $2.16K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2023.

Based on Hexagon Capital Partners's 13F filing for Q1 2023, filed 24 Apr 2023.